Analyst Price Targets — ATRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 6:37 pm | — | New Street | $6.00 | $4.42 | TheFly | Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) |
| December 19, 2025 11:28 am | — | Canaccord Genuity | $25.00 | $17.23 | TheFly | Atara Biotherapeutics price target raised to $25 from $17 at Canaccord |
| November 13, 2024 2:10 pm | Benjamin Burnett | Stifel Nicolaus | $10.00 | $7.58 | StreetInsider | Atara Biotherapeutics (ATRA) PT Raised to $10 at Stifel |
| August 16, 2024 8:55 am | Salim Syed | Mizuho Securities | $18.00 | $6.83 | TheFly | Mizuho upgrades Atara to Buy into potentially better 2025 |
| August 9, 2022 8:38 am | — | Goldman Sachs | $3.00 | $3.87 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $3 |
| May 24, 2022 7:31 am | — | Goldman Sachs | $4.00 | $4.85 | Benzinga | Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $4 |
Latest News for ATRA
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022…
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,016,616 shares, an increase of 500.8% from the December 31st total of 169,201 shares. Approximately 14.7% of the company's shares are short sold. Based on an
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRA.
U.S. House Trading
No House trades found for ATRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.